Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Inclusion Criteria: * 1\. Age 18-75 years old, gender unlimited; * 2\. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); * 3\. Confirmed as resectable/borderline resectable pancreatic cancer by CT/MRI imaging (resectability assessment refers to NCCN guidelines). For resectable pancreatic cancer, at least one of the following high-risk factors must be met: 1) CA199 \> 500 U/ml; 2) the maximum diameter of the primary tumor \> 3.0 cm; 3) Severe weight loss (BMI \< 18.5 kg/m² OR involuntary weight loss \> 15% within 6 months); 4) Severe pain (Numeric Rating Scale \[NRS\]≥ 4); 5) Definite regional lymph node metastasis (N1 or N2) OR suspicious regional lymph node metastasis (short-axis diameter of lymph nodes ≥15 mm); * 4\. Voluntarily agree to sample collection (for KRAS gene testing and post-hoc analysis); * 5\. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g/dL; absolute neutrophil count (ANC)≥1.5×10\^9/L; platelets≥80×10\^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \> 60 mL/min; * 6\. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2; * 7\. Life expectancy of at least 3 months; * 8\. Women of childbearing age should have a negative result of serum HCG or urine pregnancy tests within 72 hours prior to randomization (Postmenopau…